S
Sean A. Van Tongeren
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 21
Citations - 2352
Sean A. Van Tongeren is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Ebola virus & Marburg virus. The author has an hindex of 12, co-authored 20 publications receiving 1857 citations. Previous affiliations of Sean A. Van Tongeren include United States Department of the Army.
Papers
More filters
Journal ArticleDOI
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren,Robert Jordan,Michael K. Lo,Adrian S. Ray,Richard L. Mackman,Veronica Soloveva,Dustin Siegel,Michel Perron,Roy Bannister,Hui Hon Chung,Nate Larson,Robert G. Strickley,Jay Wells,Kelly S. Stuthman,Sean A. Van Tongeren,Nicole L. Garza,Ginger Donnelly,Amy C. Shurtleff,Cary Retterer,Dima N. Gharaibeh,Rouzbeh Zamani,Tara Kenny,Brett P. Eaton,Elizabeth C. Grimes,Lisa S. Welch,Laura Gomba,Catherine L. Wilhelmsen,Donald K. Nichols,Jonathan E. Nuss,Elyse R. Nagle,Jeffrey R. Kugelman,Gustavo Palacios,Edward Doerffler,Sean Neville,Ernest Carra,Michael O. Clarke,Lijun Zhang,Willard Lew,Bruce Ross,Queenie Wang,Kwon Soo Chun,Lydia Wolfe,Darius Babusis,Yeojin Park,Kirsten M. Stray,Iva Trancheva,Joy Y. Feng,Ona Barauskas,Yili Xu,Pamela Wong,Molly R. Braun,Mike Flint,Laura K. McMullan,Shan Shan Chen,Rachel Fearns,S. Swaminathan,Douglas L. Mayers,Christina F. Spiropoulou,William A. Lee,Stuart T. Nichol,Tomas Cihlar,Sina Bavari +61 more
TL;DR: These results show the first substantive post-exposure protection by a small-molecule antiviral compound against EBOV in nonhuman primates, and the broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenavirus, and coronavirus suggests the potential for wider medical use.
Journal ArticleDOI
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
Travis K. Warren,Jay Wells,Rekha G. Panchal,Kelly S. Stuthman,Nicole L. Garza,Sean A. Van Tongeren,Lian Dong,Cary Retterer,Brett P. Eaton,Gianluca Pegoraro,Shelley P. Honnold,Shanta Bantia,Pravin L. Kotian,Xilin Chen,Brian R. Taubenheim,Lisa S. Welch,Dena M. Minning,Y.S. Babu,William P. Sheridan,Sina Bavari +19 more
TL;DR: It is shown that BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells, and exhibits broad-spectrum antiviral activity against numerous viruses.
Journal ArticleDOI
Advanced antisense therapies for postexposure protection against lethal filovirus infections
Travis K. Warren,Kelly L. Warfield,Jay Wells,Dana L. Swenson,Kelly S Donner,Sean A. Van Tongeren,Nicole L. Garza,Lian Dong,Dan V. Mourich,Stacy Crumley,Donald K. Nichols,Patrick L. Iversen,Sina Bavari +12 more
TL;DR: Administration of positively charged phosphorodiamidate morpholino oligomers (PMOplus), delivered by various dosing strategies initiated 30–60 min after infection, protects >60% of rhesus monkeys against lethal Zaire Ebola virus (ZEBOV) and 100% of cynomolgus monkeysagainst Lake Victoria Marburg virus (MARV) infection.
Journal ArticleDOI
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus.
Sandra L. Bixler,Thomas M. Bocan,Jay Wells,Kelly S. Wetzel,Sean A. Van Tongeren,Lian Dong,Nicole L. Garza,Ginger Donnelly,Lisa H. Cazares,Jonathan E. Nuss,Veronica Soloveva,Keith A. Koistinen,Lisa S. Welch,Carol Epstein,Li Fang Liang,Dennis Giesing,Robert Lenk,Sina Bavari,Travis K. Warren +18 more
TL;DR: Favipiravir is a broad‐spectrum antiviral agent that has demonstrated efficacy against Ebola virus (EBOV) in rodents and in vivo efficacy against two filoviruses, EBOV and Marburg virus (MARV), and its pharmacokinetic profile is evaluated.
Journal ArticleDOI
Toll-Like Receptor Agonist Augments Virus-Like Particle-Mediated Protection from Ebola Virus with Transient Immune Activation
Karen A. Martins,Jesse T. Steffens,Sean A. Van Tongeren,Jay Wells,Alison A. Bergeron,Samuel P. Dickson,John M. Dye,Andres M. Salazar,Sina Bavari +8 more
TL;DR: This study explores the impact of a stabilized dsRNA mimic, polyICLC, on VLP vaccination of C57BL/6 mice and Hartley guinea pigs and shows that at dose levels as low as 100 ng, the adjuvant increased the efficacy of the vaccine in mice.